Table 3 Costs for stroke, 2003–2007, Germany
From: Cost of clinical events in health economic evaluations in Germany: a systematic review
Study | Model type | Specification of disease severity | First cycle | Costs covered | Follow-up cycles | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Time horizon | Unit cost (€) | Number of sourcesa | Direct costsb | Not specified | Time horizon | Unit cost (€) | Number of sourcesa | |||||
Hosp | Rehab | Other | ||||||||||
Year of costing: 2003 | ||||||||||||
Annemans L. Int J Clin Pract 2006; 60(9): 1129–37 [8] | Markov model | Fatal stroke | Not specified | 1,897 | 1 | Yes | No follow-up costs considered | |||||
Lamotte M. Pharmacoeconomics 2006; 24(2): 155–69 [16] | Markov model | Fatal stroke | Acute period | 1,897 | NA | Yes | No follow-up costs considered | |||||
Annemans L. Int J Clin Pract 2006; 60(9): 1129–37 [8] | Markov model | Non-fatal stroke | Not specified | 3,390 | 1 | Yes | Annual follow-up costs | 676 | 1 | |||
Lamotte M. Pharmacoeconomics 2006; 24(2): 155–69 [16] | Markov model | Non-fatal stroke | Not specified | 3,390 | NA | Yes | Annual follow-up costs | 676 | 1 | |||
Liebl A. Gesund ökon Qual Manag 2006; 11: 105–11 [18] | Decision tree | Stroke | First 3 months | 12,068 | 1 | Yes | Months 4–12 | 1,491 | 1 | |||
Annual follow-up costs | 520 | > 1 | ||||||||||
Year of costing: 2004 | ||||||||||||
Lamotte M. Pharmacoeconomics. 2006; 24(8): 783–95 [17] | Decision tree | Stroke | Acute period | 3,390 | 1 | Yes | No follow-up costs considered | |||||
Roze S. Curr Med Res Opin 2006; 22(7): 1415–24 [23] | Semi-Markov model | Fatal stroke | Not specified | 9,006 | 1 | Yes | No follow-up costs considered | |||||
Rasch A. Suchtmed 2009; 11(2): 47–55 [21] | Markov model | Stroke | First 12 months | 10,149 | > 1 | Yes | Annual follow-up costs | 4,364 | > 1 | |||
Brüggenjürgen B. Eur J Health Econ 2007; 8(1): 51–7 [12] | Markov model | Stroke | First 12 months | 17,734 | 1 | Yes | Yes | Yes | Annual follow-up costs | 5,614 | 1 | |
Roze S. Curr Med Res Opin 2006; 22(7): 1415–24 [23] | Semi-Markov model | Stroke | Year of event | 19,399 | 1 | Yes | Annual follow-up costs | 6,060 | 1 | |||
Gandjour A. Health Policy 2007; 83(2–3): 257–67 [14] | Markov model | Stroke | First 12 months | 24,936 | > 1 | Yes | Post-year 1 | 5,465 | > 1 | |||
Year of costing: 2005 | ||||||||||||
Scherbaum WA. Cost Eff Resour Alloc 2009; 7: 9 [25] | Semi-Markov model | TIA | Year of event | 2,354 | NA | Yes | Annual follow-up costs | 0 | NA | |||
Claes C. Med Klin 2008; 103: 778–87 [13] | Markov model | Fatal stroke | Acute period | 2,500 | NA | Yes | No follow-up costs considered | |||||
Claes C. Med Klin 2008; 103: 778–87 [13] | Markov model | Stroke | Acute period | 7,000 | NA | Yes | Rehab after acute event | 7000 | NA | |||
Scherbaum WA. Cost Eff Resour Alloc 2009; 7: 9 [25] | Semi-Markov model | Stoke | Year of event | 10,524 | > 1 | Yes | Annual follow-up costs | 6,178 | > 1 | |||
Weber CJ. Diabetes Sci Technol 2007; 1(5): 676–84 [28] | Markov model | Stroke | Year of event | 20,811 | 1 | Yes | Year after event | 6,501 | 1 | |||
Berger K. Curr Med Res Opin 2008; 24(1): 267–74 [11] | Markov model | Stroke | Initial treatment | 4,692 | NA | Yes | First 6 months after event | 6,664 | NA | |||
Stroke | Second 6 months after event | 5,936 | NA | |||||||||
Stroke | Subsequent 6- month intervals | 5,251 | ||||||||||
Berg J. Clin Ther 2007; 29(6): 1184–202 [9] | Decision tree and Markov model | Stroke | Month 1 | 6813 | 1 | Yes | Months 2–12 | 12,112 | 1 | |||
Stroke | Annual follow-up costs | 5,600 | 1 | |||||||||
Year of costing: 2006 | ||||||||||||
Valentine WJ. Adv Ther 2008; 25(6): 567–84 [27] | Semi-Markov model | Fatal stroke | Not specified | 9,488 | 1 | Yes | No follow-up costs considered | |||||
Schaufler TM. Gesund ökon Qual Manag 2009; 14: 71–5 [24] | Markov model | Stroke | First 12 months | 18,649 | 1 | Yes | Annual follow-up costs | 4,416 | 1 | |||
Valentine WJ. Adv Ther 2008; 25(6): 567–84 [27] | Semi-Markov model | Stroke | Year of event | 20,439 | 1 | Yes | Annual follow-up events | 6,385 | 1 | |||
Berg J. Curr Med Res Opin 2008; 24(7): 2089–101 [10] | Decision tree and Markov model | Stroke | Month 1 | 6,912 | > 1 | Yes | Months 2–12 | 12,289 | 1 | |||
Stroke | Annual follow-up costs | 5,681 | 1 | |||||||||
Year of costing: 2007 | ||||||||||||
Schwander B. Value Health 2009; 12(6): 857–71 [26] | Markov model | TIA | First 12 months | 3,365 | > 1 | Yes | Annual follow-up costs | 0 | NA | |||
Stroke | First 12 months | 17,629 | > 1 | Yes | Annual follow-up costs | 7,337 | > 1 | |||||
Mittendorf T. Diabetes Obes Metab 2009; 11(11): 1068–79 [19] | Semi-Markov model | Fatal stroke | Year of event | 19,534 | 1 | Yes | No follow-up costs considered | |||||
Stroke | Year of event | 19,534 | 1 | Yes | Annual follow-up costs | 5,780 | 1 | |||||
Year of costing: not specified | ||||||||||||
Neeser K. J Kardiol 2006; 13: 131–20 [20] | Markov model | Fatal ischaemic stroke | Not specified | 3,573 | 1 | Yes | No follow-up costs considered | |||||
Severe bleeding | Not specified | 9,000 | > 1 | Yes | After initial hospitalization until end of first year | 5,003 | 1 | |||||
Ischaemic stroke | Acute period | 4,679 | 1 | Yes | From second year onwards | 12,500 | 1 | |||||